Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Insights

- PMLiVE

Havas Lynx appoints three new creative directors

Paul Kinsella, Louise Shipley and Phil Howells join the agency

- PMLiVE

Astellas: Ten years young

Ken Jones and Sef Kurstjens on the company's progress and plans

- PMLiVE

Roche and AZ claim FDA breakthrough status for new drugs

Designation could speed up development for Roche’s ocrelizumab and AZ’s durvalumab 

- PMLiVE

Forging a path in specialty care

Takeda’s Marc Princen on the company’s plans to build a reputation in oncology, gastroenterology and vaccine

- PMLiVE

Mismanagement of Cancer Drugs Fund “unacceptable”

Influential committee of MPs finds the government still unable to assess CDF's patient benefit

Harnessing complexity

Companion diagnostics in oncology

Roche Basel Switzerland

Roche shares slip as profits miss expectations

But shows solid sales growth thanks to its oncology portfolio

EISAI

Eisai’s Lenvima gets FDA priority review for kidney cancer

The oncology treatment could now be approved in the US before the summer

Brain cancer glioblastoma

Glioblastoma market set for ‘meteoric rise’

Sales of treatments for rare brain cancer predicted to reach $3.3bn by 2024

- PMLiVE

Merck & Co buys IOmet to boost immuno-oncology tech

Reports suggest it paid up to £280m for the Scottish biopharma company

- PMLiVE

AZ takes majority stake in cancer drug developer Acerta

Will pay $4bn for a 55% share in the Dutch biopharma company

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links